The Conversation (0)
Helix BioPharma Corp. (TSX:HBP) announced that it has started its US Phase I study of L-DOS47 combined with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous non-small cell lung cancer (LDOS001).
Helix BioPharma Corp. (TSX:HBP) announced that it has started its US Phase I study of L-DOS47 combined with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous, non-small cell lung cancer (LDOS001).
It’s taking place in Texas, and two additional sites in the US are expected to participate.
As quoted in the press release:
LDOS001 is a Phase I, open label, dose escalation study of the company’s lead product L-DOS47. The primary objective of the study is to determine the safety and tolerability of L-DOS47 in combination treatment with pemetrexed/carboplatin. The study will also evaluate the potential clinical benefit of L-DOS47 with this combination. Other exploratory objectives include the evaluation of the L-DOS47 pharmacokinetics and immunogenicity.
Click here to read the full Helix BioPharma Corp. (TSX:HBP) press release.